Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-4618 52-week extension study in overactive bladder
2010-022121-15Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of vibegron in overactive bladder (OAB) (3 arms), sponsored by Merck & Co. Primary endpoints: Change from baseline in average number of daily micturitions and Dose-related reduction in average number of daily micturitions versus placebo at Week 8. Started Feb 2011; status: completed.
02
Drugs
vibegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on 2010-022121-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022121-15.